shares of pfizer were upgraded to buy from neutral at ubs with the firm writing that it expects antiviral pill paxlovid to reach sales of at least 14 billion next year or 40 above wall street expectations ubs analyst colin bristow in a research note monday also boosted the price target on the stock to 60 from 52